..if indeed it turns out to be preemptive, why wouldn't Sandoz/MNTA have done it earlier?
As noted in #msg-60686112, injected drugs typically don’t need bioequivalence studies; hence, NVS/MNTA may have deferred running such a study until they could ascertain that this matter is on the critical path.
It's also my understanding that these studies are pretty small…
Yes—small and quick.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.